TrialCompass TCL
Back to results
Phase 2Not yet recruitingPriority 2 · High priorityNCT07180771

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is testing BR101801 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 19 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

BR101801 (DRUG): Patients will receive 200mg capsules (100mg+100mg)

Drugs / treatments
BR101801
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.

NCT07180771

Phase: Phase 2 | Status: Not yet recruiting | Priority: High

Plain-language summary

This Phase 2 trial is testing BR101801 for people whose T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 19 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

BR101801 (DRUG): Patients will receive 200mg capsules (100mg+100mg)

Drugs / treatments: BR101801

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 44 patients

Primary endpoint: Confirmed Objective Response Rate (ORR) (CR + PR) assessed by a blinded independent reviewer at the central lab according to the 2014 Lugano criteria

Ages: 19 Years to —

Start date: 2026-02 | Est. completion: 2027-09

Locations

0 US sites · 0 total

Contact

Shinyoung Oh | syoh@boryung.co.kr | +82 2-708-8000

Sponsor: Boryung Pharmaceutical Co., Ltd (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07180771

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.